Shandong Cancer Hospital and Institute: Lung Neoplasms trials

The registry lists 10 Lung Neoplasms studies with Shandong Cancer Hospital and Institute as lead sponsor. 1 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 7Phase 3 2Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line ChemoradiotherapyRecruitingNCT04829708Phase 3
• A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung CancerTerminatedNCT04958993Phase 1/2
• A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer PatientsStatus unknownNCT04619563Phase 2
• A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung CancerStatus unknownNCT04619537Phase 2
• SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLCActive, not recruitingNCT04562337Phase 2
• A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line TreatmentStatus unknownNCT04560244Phase 2
• Individualized Adaptive Radiotherapy Based on PET/CT and IMRT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT02790190Phase 3
• Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial RadiotherapyStatus unknownNCT02577393Phase 2
• Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung CancerStatus unknownNCT02195453Phase 4
• Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung CancerStatus unknownNCT02191059Phase 2